These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
198 related articles for article (PubMed ID: 31502767)
1. Survey of current treatment practices for venous thromboembolism in patients with cystic fibrosis. Ratté MT; Jones AE; Witt DM; Young DC Pediatr Pulmonol; 2020 Jan; 55(1):149-155. PubMed ID: 31502767 [TBL] [Abstract][Full Text] [Related]
2. Evaluation of oral anticoagulants for the extended treatment of venous thromboembolism using a mixed-treatment comparison, meta-analytic approach. Rollins BM; Silva MA; Donovan JL; Kanaan AO Clin Ther; 2014 Oct; 36(10):1454-64.e3. PubMed ID: 25092394 [TBL] [Abstract][Full Text] [Related]
3. Comparison of differences in medical costs when new oral anticoagulants are used for the treatment of patients with non-valvular atrial fibrillation and venous thromboembolism vs warfarin or placebo in the US. Amin A; Bruno A; Trocio J; Lin J; Lingohr-Smith M J Med Econ; 2015 Jun; 18(6):399-409. PubMed ID: 25586203 [TBL] [Abstract][Full Text] [Related]
4. Venous thromboembolism management in people with cystic fibrosis. Abbinanti A; Witt DM; Saunders J; Jones AE; Young DC Pediatr Pulmonol; 2024 Mar; 59(3):584-591. PubMed ID: 38038058 [TBL] [Abstract][Full Text] [Related]
5. Effectiveness and Safety of Apixaban, Low-Molecular-Weight Heparin, and Warfarin among Venous Thromboembolism Patients with Active Cancer: A U.S. Claims Data Analysis. Cohen A; Keshishian A; Lee T; Wygant G; Rosenblatt L; Hlavacek P; Mardekian J; Wiederkehr D; Sah J; Luo X Thromb Haemost; 2021 Mar; 121(3):383-395. PubMed ID: 33171521 [TBL] [Abstract][Full Text] [Related]
6. Venous thromboembolism management: where do novel anticoagulants fit? Spyropoulos AC; Turpie AG Curr Med Res Opin; 2013 Jul; 29(7):783-90. PubMed ID: 23659584 [TBL] [Abstract][Full Text] [Related]
7. Patient satisfaction after conversion from warfarin to direct oral anticoagulants for patients on extended duration of anticoagulation for venous thromboembolism - The SWAN Study. Hendriks T; McGregor S; Rakesh S; Robinson J; Ho KM; Baker R PLoS One; 2020; 15(6):e0234048. PubMed ID: 32497116 [TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of Apixaban Versus Other Oral Anticoagulants for the Initial Treatment of Venous Thromboembolism and Prevention of Recurrence. Lanitis T; Leipold R; Hamilton M; Rublee D; Quon P; Browne C; Cohen AT Clin Ther; 2016 Mar; 38(3):478-93.e1-16. PubMed ID: 26922297 [TBL] [Abstract][Full Text] [Related]
9. Evaluation of anticoagulation selection for acute venous thromboembolism. Badreldin H; Nichols H; Rimsans J; Carter D J Thromb Thrombolysis; 2017 Jan; 43(1):74-78. PubMed ID: 27592341 [TBL] [Abstract][Full Text] [Related]
10. New anticoagulants for the treatment of venous thromboembolism. Fernandes CJ; Alves Júnior JL; Gavilanes F; Prada LF; Morinaga LK; Souza R J Bras Pneumol; 2016 Apr; 42(2):146-54. PubMed ID: 27167437 [TBL] [Abstract][Full Text] [Related]
12. Determining the impact of culture on venous thromboembolism prevention in trauma patients: A Southwestern Surgical Congress Multicenter trial. Regner JL; Shaver CN; Am J Surg; 2019 Jun; 217(6):1030-1036. PubMed ID: 30503515 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data. Kushnir M; Choi Y; Eisenberg R; Rao D; Tolu S; Gao J; Mowrey W; Billett HH Lancet Haematol; 2019 Jul; 6(7):e359-e365. PubMed ID: 31133411 [TBL] [Abstract][Full Text] [Related]
14. All-Cause Mortality Risk with Direct Oral Anticoagulants and Warfarin in the Primary Treatment of Venous Thromboembolism. Roetker NS; Lutsey PL; Zakai NA; Alonso A; Adam TJ; MacLehose RF Thromb Haemost; 2018 Sep; 118(9):1637-1645. PubMed ID: 30103250 [TBL] [Abstract][Full Text] [Related]
15. Profile of Patients Diagnosed With Acute Venous Thromboembolism in Routine Clinical Practice: The RE-COVERY DVT/PE™ Study. Goldhaber SZ; Ageno W; Casella IB; Chee KH; Schellong S; Singer DE; Desch M; Reilly PA; Donado E; Tang W; Voccia I; Schulman S Am J Med; 2020 Aug; 133(8):936-945. PubMed ID: 32325043 [TBL] [Abstract][Full Text] [Related]
16. Effects of different anticoagulant drugs on the prevention of complications in patients after arthroplasty: A network meta-analysis. Gao JH; Chu XC; Wang LL; Ning B; Zhao CX Medicine (Baltimore); 2017 Oct; 96(40):e8059. PubMed ID: 28984761 [TBL] [Abstract][Full Text] [Related]
17. New oral anticoagulants for the treatment of venous thromboembolism. Agnelli G; Becattini C; Franco L Best Pract Res Clin Haematol; 2013 Jun; 26(2):151-61. PubMed ID: 23953903 [TBL] [Abstract][Full Text] [Related]
18. Retrospective comparison of low molecular weight heparin vs. warfarin vs. oral Xa inhibitors for the prevention of recurrent venous thromboembolism in oncology patients: The Re-CLOT study. Alzghari SK; Seago SE; Garza JE; Hashimie YF; Baty KA; Evans MF; Shaver C; Herrington JD J Oncol Pharm Pract; 2018 Oct; 24(7):494-500. PubMed ID: 28714376 [TBL] [Abstract][Full Text] [Related]
19. Comparison of the Novel Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in the Initial and Long-Term Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis. Cohen AT; Hamilton M; Mitchell SA; Phatak H; Liu X; Bird A; Tushabe D; Batson S PLoS One; 2015; 10(12):e0144856. PubMed ID: 26716830 [TBL] [Abstract][Full Text] [Related]
20. Rivaroxaban and Apixaban for Initial Treatment of Acute Venous Thromboembolism of Atypical Location. Janczak DT; Mimier MK; McBane RD; Kamath PS; Simmons BS; Bott-Kitslaar DM; Lenz CJ; Vargas ER; Hodge DO; Wysokinski WE Mayo Clin Proc; 2018 Jan; 93(1):40-47. PubMed ID: 29217335 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]